Betaseron Adds Secondary Progressive MS Use; Limited To Relapsing Patients
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Berlex/Chiron’s Betaseron indication has been expanded to include secondary progressive multiple sclerosis, but approval is limited to the subset of patients who continue to have relapsing disease.